Robert Samstein, MD, PhD

Robert Samstein, MD, PhD practices at Mount Sinai, where research focuses on biomarkers for immunotherapy response in non-small cell lung cancer (NSCLC) and other solid tumors.

Published Articles (1)

PD-L1 Alone Isn't Enough, and Neither Is TMB: What Would a Real Immunotherapy Biomarker Look Like?

October 10, 2026

Only a minority of patients meaningfully benefit from immunotherapy, and right now we largely rely on a single, binary metric (PD-L1) to try to select who that is.